Answer
In phase 3 studies of Symkevi with ivacaftor in patients aged 12 years and older, the most common adverse reactions were headache (14% versus 11% on placebo) and nasopharyngitis (12% versus 10% on placebo).
Sources for this answer
- Symkevi 100 mg/150 mg tablets PLGB 22352/0003Vertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.8 Undesirable effects · Version 14Document updated
Sources checked